Why Down Syndrome Patients Are Predisposed to Leukemia
Children with Down syndrome (trisomy 21) have a 14- to 20-fold increased risk of developing acute leukemia due to the constitutional presence of an extra copy of chromosome 21, which creates a unique biological environment that cooperates with acquired GATA1 mutations to drive leukemogenesis, particularly in the megakaryocytic lineage. 1
The Molecular Mechanism
The predisposition operates through a specific multi-step pathway that is now well-characterized:
Constitutional Trisomy 21 as the Foundation
The extra copy of chromosome 21 is itself a constitutional chromosome abnormality that predisposes to myeloid neoplasms 2. This creates an altered hematopoietic environment from conception that fundamentally changes how blood cells develop and respond to additional genetic hits.
The Critical GATA1 Mutation
The key mechanistic step is the acquisition of mutations in exon 2 of the GATA1 gene, which occur in fetal liver hematopoiesis and result in a truncated protein called GATA1s 1. This mutation:
- Results in loss of the activation domain of this critical hematopoietic transcription factor
- Is arguably present in all cases of both transient abnormal myelopoiesis (TAM) and myeloid leukemia in Down syndrome (ML-DS) 3
- Originates from fetal liver-derived megakaryocyte progenitors 1
The Unique Cooperation Between Trisomy 21 and GATA1s
There is a unique functional cooperation between trisomy 21 and GATA1s-generating mutations that drives leukemogenesis 4. This cooperation is so specific that:
- When germline GATA1s mutations are present without Down syndrome, affected individuals acquire trisomy 21 or tetrasomy 21 somatically in their leukemic cells 4
- The resulting leukemia characteristics overlap completely with ML-DS, including age of onset, immunophenotype, and drug sensitivity 4
- This demonstrates the combination requires both elements regardless of which is primary or secondary 4
The Two-Step Progression Model
Step 1: Transient Abnormal Myelopoiesis (TAM)
- Occurs in approximately 5% of newborns with Down syndrome 1
- Represents self-limited expansion of fetal liver-derived megakaryocyte progenitors 3
- Characterized by GATA1 mutations 1
- Usually disappears spontaneously within 4-10 weeks 1
Step 2: Progression to Myeloid Leukemia
- Within the first 4 years of life, 10-20% of infants with TAM develop ML-DS 1
- Progression requires additional mutations in:
Leukemia Types in Down Syndrome
Myeloid Leukemia (More Common)
- Predominantly acute megakaryoblastic leukemia 4
- Occurs primarily in early childhood (before age 4 years) 4
- Unique immunophenotype and gene expression patterns 4
- Paradoxically has excellent outcomes with reduced-intensity chemotherapy due to extreme sensitivity to cytarabine 5
Acute Lymphoblastic Leukemia
- Also occurs at increased frequency 7
- Different cytogenetic subgroups compared to non-DS ALL 1
- Frequent aberrant CRLF2 expression, JAK2 mutations, and RAS pathway-activating mutations 6
Clinical Implications
The constitutional nature of trisomy 21 means that when trisomy 21 is found in all cells on cytogenetic analysis of a myeloid neoplasm, clinicians should verify the patient's phenotype if unknown, as this may represent unrecognized Down syndrome 2.
The predisposition is so strong that Down syndrome is specifically listed among constitutional chromosome abnormalities associated with myeloid neoplasm predisposition, alongside rare Robertsonian translocations 2.
For surveillance purposes, Down syndrome patients are classified as having lower risk for requiring intensive monitoring compared to other leukemia predisposition syndromes 7. Clinical bone marrow evaluation may be omitted in asymptomatic children with stable blood counts, though baseline evaluation should be considered 7.